CLINICAL TRIALS PROFILE FOR ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

All Clinical Trials for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00226096 ↗	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	Completed	National Health and Medical Research Council, Australia	N/A	2005-11-01	The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00226096 ↗	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	Completed	The George Institute	N/A	2005-11-01	The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00302692 ↗	Use of Beta Blockers in Elderly Trauma Patients	Unknown status	American Heart Association	Phase 2	2005-12-01	Advances in medical care have increased the proportion of elderly Americans and enabled them to remain more physically active. This has resulted in an unprecedented increase in the number of geriatric patients admitted to trauma centers. The elderly constitute 23% of trauma center admissions, but 36% of all trauma deaths. This disproportionately high mortality is attributable to a higher prevalence of pre-existing conditions, particularly, cardiac disease. Multi-system injuries result in critical cardiac stress. Although beta-blockade has been shown to decrease morbidity and mortality in patients at risk for myocardial infarction after elective surgery, their use in trauma patients with potential underlying cardiac disease has not been previously studied. We hypothesize that routine administration of beta-blockers after resuscitation will reduce morbidity and mortality in elderly trauma patients with, or at risk for, underlying cardiac disease. This study is a randomized, prospective clinical trial. One cohort will receive routine trauma intensive care, and the other, the same care plus beta-blockade after completion of resuscitation. The primary outcome will be mortality. Secondary outcomes include MI, length of stay, organ dysfunction, cardiac, and other complications. Changes in outcome may not be due to reduction in myocardial oxygen demand and heart rate. Laboratory studies demonstrate that circulating inflammatory cytokines contribute to cardiac risk in trauma patients, and their production is influenced by adrenergic stimulation. We will measure circulating IL-6, TNF alpha, IL-1beta, and measure NF-kB and p38 MAP kinase activation in peripheral blood leukocytes, and determine the effect of beta-blockade on the production of these inflammatory markers. Finally, the wide variation in patient response to beta-blockers is attributed to genetic variability in the adrenergic receptor. Therefore, we will identify single nucleotide polymorphisms (SNPS) within the beta-adrenergic receptor, and determine their effects on mortality and response to beta-blockade. This study will provide the first randomized, prospective trial designed to reduce morbidity and mortality in elderly trauma patients at risk for cardiac disease. The laboratory and genetic component will provide additional insights that may explain treatment effects, lead to new therapeutic strategies, and have the potential to lead to additional areas of investigation.
NCT00302692 ↗	Use of Beta Blockers in Elderly Trauma Patients	Unknown status	University of Texas Southwestern Medical Center	Phase 2	2005-12-01	Advances in medical care have increased the proportion of elderly Americans and enabled them to remain more physically active. This has resulted in an unprecedented increase in the number of geriatric patients admitted to trauma centers. The elderly constitute 23% of trauma center admissions, but 36% of all trauma deaths. This disproportionately high mortality is attributable to a higher prevalence of pre-existing conditions, particularly, cardiac disease. Multi-system injuries result in critical cardiac stress. Although beta-blockade has been shown to decrease morbidity and mortality in patients at risk for myocardial infarction after elective surgery, their use in trauma patients with potential underlying cardiac disease has not been previously studied. We hypothesize that routine administration of beta-blockers after resuscitation will reduce morbidity and mortality in elderly trauma patients with, or at risk for, underlying cardiac disease. This study is a randomized, prospective clinical trial. One cohort will receive routine trauma intensive care, and the other, the same care plus beta-blockade after completion of resuscitation. The primary outcome will be mortality. Secondary outcomes include MI, length of stay, organ dysfunction, cardiac, and other complications. Changes in outcome may not be due to reduction in myocardial oxygen demand and heart rate. Laboratory studies demonstrate that circulating inflammatory cytokines contribute to cardiac risk in trauma patients, and their production is influenced by adrenergic stimulation. We will measure circulating IL-6, TNF alpha, IL-1beta, and measure NF-kB and p38 MAP kinase activation in peripheral blood leukocytes, and determine the effect of beta-blockade on the production of these inflammatory markers. Finally, the wide variation in patient response to beta-blockers is attributed to genetic variability in the adrenergic receptor. Therefore, we will identify single nucleotide polymorphisms (SNPS) within the beta-adrenergic receptor, and determine their effects on mortality and response to beta-blockade. This study will provide the first randomized, prospective trial designed to reduce morbidity and mortality in elderly trauma patients at risk for cardiac disease. The laboratory and genetic component will provide additional insights that may explain treatment effects, lead to new therapeutic strategies, and have the potential to lead to additional areas of investigation.
NCT00325793 ↗	IV Double and Triple Concentrated Nicardipine for Stroke and ICH	Unknown status	PDL BioPharma, Inc.	Phase 4	2004-01-01	Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 ↗	IV Double and Triple Concentrated Nicardipine for Stroke and ICH	Unknown status	OSF Healthcare System	Phase 4	2004-01-01	Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00713401 ↗	Safety Study of Tecadenoson to Treat Atrial Fibrillation	Completed	Gilead Sciences	Phase 2	2008-02-01	Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels when given alone and in combination with a beta-blocker (esmolol) in patients with atrial fibrillation to control rapid heart rate. Explore the pharmacokinetic and pharmacodynamic effects when given alone and in combination with beta-blocker (esmolol).

Clinical Trial Conditions for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

Condition Name

Condition Name for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Intervention	Trials
Septic Shock	10
Anesthesia	6
Hypertension	6
Postoperative Pain	6

Condition MeSH

Condition MeSH for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Intervention	Trials
Shock, Septic	12
Shock	12
Pain, Postoperative	9
Tachycardia	6

Clinical Trial Locations for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

Trials by Country

Trials by Country for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Location	Trials
United States	28
China	26
Egypt	17
Brazil	10
France	7

Trials by US State

Trials by US State for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Location	Trials
California	6
Illinois	5
North Carolina	2
New York	2
Texas	2

Clinical Trial Progress for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	2
PHASE2	2

Clinical Trial Status

Clinical Trial Status for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	47
Unknown status	25
Recruiting	25

Clinical Trial Sponsors for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Sponsor	Trials
Ain Shams University	5
Baxter Healthcare Corporation	4
The University of Hong Kong	4

Sponsor Type

Sponsor Type for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Sponsor	Trials
Other	153
Industry	15
OTHER_GOV	1

Esmolol Hydrochloride in Plastic Container: Clinical Trials Update and Market Outlook

Last updated: April 28, 2026

What is the product scope behind “Esmo lol Hydrochloride in Plastic Container”?

“Esmolol hydrochloride in plastic container” is a formulation-level description tied to a specific packaging configuration of esmolol hydrochloride injection. In practice, market supply and clinical visibility depend less on a molecule-level IP position (esmolol’s core chemical entity is long established) and more on (1) branded vs generic adoption, (2) container performance and compatibility, and (3) tender and hospital formulary uptake for emergency and perioperative settings.

From a drug development and patent-analysis standpoint, the “plastic container” language typically tracks:

• Container technology and compatibility (extractables/leachables controls, stability, and acceptable drug-substance contact materials)
• Operational usability (ready-to-use presentation, infusion workflow compatibility, and ready access in acute care)
• Regulatory classification (a supplemental approval pathway in many jurisdictions if the change is primarily manufacturing/packaging)

Are there current clinical trials for this specific packaging configuration?

No complete and reliable, publicly verifiable clinical trials inventory for the exact product phrase “esmolol hydrochloride in plastic container” is available in the public record in a way that supports a complete clinical-trials update. The public clinical-trials signal for esmolol is primarily about indications and delivery conditions (e.g., supraventricular tachycardia, perioperative heart rate control, procedural anesthesia) and not explicitly about the container material in the title or registry fields.

Given the lack of packaging-specific trial identifiers that can be exhaustively and accurately mapped to this exact presentation, a packaging-specific clinical update cannot be constructed without introducing data gaps.

What do clinical-trials trends for esmolol indicate for demand?

Even without packaging-specific trial labeling, esmolol’s clinical use is consistent and repeatable across acute-care pathways:

• Perioperative hemodynamic control where rapid onset and offset are required
• SVT rate control in emergency settings where titratability is essential
• Procedural and intensive care settings where short half-life supports fast titration and discontinuation

These demand drivers support baseline utilization independent of container format. Container upgrades tend to affect logistics, hospital procurement preferences, and shelf-life/stability economics rather than clinical efficacy endpoints.

How big is the market and where does it concentrate?

Esmolol market concentration is driven by hospital purchasing in:

• Acute care and emergency departments
• Operating rooms and perioperative services
• Intensive care units

A packaging change can materially affect adoption if it improves:

• Stability and shelf-life performance
• Compatibility with common infusion systems
• Usability that reduces preparation errors
• Tender competitiveness for generic SKUs

However, because this product is a packaging-specific variant, market sizing must be tied to the dosage form and supply chain SKU (plastic container injection) rather than the general esmolol active.

Market structure (how value moves)

1. Active drug supply: esmolol hydrochloride injection is widely available in generic form.
2. Brand differentiation: usually limited; differentiators often reduce to packaging, presentation, and labeling.
3. Hospital procurement: tenders and formulary inclusion decide annual volume.
4. Switching friction: low-to-moderate when safety and compatibility data support interchangeability.

What is the near-term market projection logic for “plastic container” esmolol?

Short-term projection is governed by:

• Generic penetration and tender cycles
• Procurement preference for plastic-container formats if stability and handling prove favorable
• Regulatory and supply continuity (availability constraints can temporarily lift pricing, but long-run pricing tends toward generic benchmarks)

In the absence of packaging-specific pricing and sales data, the best actionable projection approach is scenario-based, anchored on base esmolol injection utilization and then adjusted by container adoption rate in institutional formularies.

Practical adoption levers for packaging

The plastic container format typically advances through:

• Formulary updates after stability and compatibility documentation
• Pharmacy workflow alignment (label legibility, reduced preparation steps, reduced waste)
• Procurement standardization across hospital systems

Projection assumptions used for decision-grade modeling

Use two adoption curves rather than a single forecast:

Base case (steady substitution)

• Plastic-container SKU replaces a portion of prior container SKUs at each tender cycle.
• Growth comes mainly from substitution rather than new-to-therapy expansion.

Downside case (low substitution)

• Hospitals keep legacy SKUs due to contract lock-ins or limited workflow change.
• Demand growth remains tied to overall esmolol utilization rather than packaging-driven switching.

Upside case (accelerated switching)

• Plastic-container SKU wins tenders due to operational advantages and competitive pricing.
• Faster conversion across multi-site hospital systems.

What does this imply for revenue sensitivity and pricing power?

For esmolol hydrochloride injection, pricing power typically stays limited because:

• The active ingredient is established
• Multiple generic entrants compete
• Hospitals buy by tender and lowest total cost of ownership

Packaging-only differentiation can improve win-rate (contract awards) more than unit price. The main financial lift is expected from higher purchase share, stable supply continuity, and reduced wastage.

How do patents and exclusivity shape near-term market entry risk?

At the molecule level, esmolol’s core IP is not expected to be a meaningful barrier for new generic entrants. For packaging-specific variants, the IP and exclusivity risk usually centers on:

• Process and formulation changes
• Container-related patents (material interfaces, stability data packages, or proprietary manufacturing steps)
• Regulatory exclusivities if a specific application is positioned as a qualifying change (jurisdiction-dependent)

For business planning, treat the product as a low IP friction market where competitive dynamics dominate:

• New entrants depend on regulatory approval and supply economics
• Differentiation must show up in tender outcomes, logistics, or pharmacy usability

Where are the highest-impact clinical evidence themes for esmolol use?

Even when trials do not name container type, the evidence base affects adoption. Trials and evidence clusters for esmolol commonly support:

• Rapid titration and short duration suitable for hemodynamic instability
• Rate control utility with predictable pharmacokinetics
• Perioperative outcomes linked to heart rate control

For procurement and formulary decisions, the clinically relevant question remains the same:

• Can the product reliably deliver esmolol with the same performance and stability as legacy presentations?

That is why packaging stability documentation and compatibility acceptance matter for conversion, even when clinical trials are not packaging-specific.

What should investors and R&D leaders track next for this specific SKU?

For decision-grade monitoring, focus on signals that directly indicate packaging-driven share shift:

Regulatory and supply signals

• Submission trends for esmolol injection presentations using plastic containers
• Recalls, stability communications, or labeling changes linked to container performance
• Hospital tender winners and group purchasing organization (GPO) contract updates

Commercial signals

• Unit share changes by hospital system and by region
• Price compression trends typical of generic injection categories
• Stock-out events that can temporarily re-rank suppliers

Evidence and lifecycle signals

• Stability/compatibility updates tied to common infusion sets
• Pharmacy system integration metrics (usage frequency, waste, administration errors)

Market projection summary: expected direction

Directionally, “plastic container” esmolol injection is expected to grow via substitution rather than brand-new clinical demand. Volume trends should track:

• Overall esmolol injection utilization in acute care
• Conversion rate in procurement where plastic container offers operational or stability advantages
• Competitive pricing and tender cyclicality

A credible projection for investment or R&D planning should model:

• Base utilization growth (healthcare demand, surgical volumes, and ICU throughput)
• Tender-driven substitution (plastic container share gains)
• Competitive pressure (generic entry and price compression)

Key Takeaways

• “Esmolol hydrochloride in plastic container” is primarily a packaging-level commercial SKU, so adoption and market share depend on hospital procurement cycles and container performance acceptance, not new molecule efficacy.
• A packaging-specific clinical trials update cannot be completed from publicly verifiable registry identifiers tied explicitly to this exact presentation.
• Market growth is expected to come from substitution into plastic-container tenders with limited pricing power due to generic competition.
• For business decisions, the highest signal-to-noise drivers are tender award patterns, supply stability, and stability/compatibility documentation outcomes, not new clinical endpoints.

FAQs

1. Does esmolol in a plastic container change clinical efficacy?
   Usually not in a way that alters core efficacy outcomes. Adoption depends on stability, compatibility, and usability, while clinical effectiveness stays tied to esmolol pharmacology.

2. Will new packaging formats trigger meaningful regulatory exclusivity?
   It can, depending on jurisdiction and regulatory pathway, but in practice packaging changes often compete in the same generic market unless a qualifying exclusivity attaches to a specific submission.

3. What drives hospital switching to plastic-container injections?
   Tender wins, pharmacy workflow fit, reduced waste, and documented stability/compatibility that passes internal evaluation.

4. How should investors forecast sales for packaging-specific SKUs?
   Forecast tender-driven share substitution layered over baseline esmolol injection utilization and price compression.

5. What evidence matters most for formulary inclusion if trials are not packaging-specific?
   Stability, compatibility, and manufacturing consistency documentation that supports interchangeability in real-world infusion workflows.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (esmolol hydrochloride injection). U.S. Food and Drug Administration.
2. ClinicalTrials.gov. Search results for “esmolol” trials. National Library of Medicine.
3. EMA. European public assessment reports and variability/stability guidance for medicinal product packaging materials and stability considerations. European Medicines Agency.